title: Influences on blockade by t-butylbicyclo-phosphoro-thionate of GABA(A) receptor spontaneous gating, agonist activation and desensitization.
abstract: Picrotoxin and t-butylbicyclophosphorothionate (TBPS) are GABA(A) receptor (GABA(A)R) open channel blockers. However, picrotoxin displaceable [(35)S]TBPS binding to α1β2γ2 GABA(A)Rs occurs in the absence of GABA, suggesting that access to the binding site is independent of activation. Alternatively, spontaneous gating may provide access to the channel. In the absence of episodic GABA application, picrotoxin and TBPS blocked (by 91 ± 3% and 85 ± 5%, respectively) GABA-evoked currents mediated by α1β2γ2 receptors. We used two approaches to inhibit spontaneous GABA(A)R gating, bicuculline, which inhibits spontaneous current in the absence of exogenous agonist and the α1(K278M) mutant subunit. Whole-cell patch-clamp recordings demonstrated that α1(K278M)β2γ2 receptors have negligible spontaneous gating. Application of bicuculline to α1β2γ2 receptors in the absence of exogenous GABA caused a 35% reduction of current blockade by TBPS and reduced [(35)S]TBPS binding by 25%. Consistent with this, in the absence of exogenous GABA, α1(K278M)β2γ2 receptors exhibited reduced blockade by TBPS current compared to wild-type receptors. These data suggest that a decrease in spontaneous gating reduces accessibility of TBPS to its binding site. GABA application during picrotoxin or TBPS administration enhanced α1β2γ2 receptor blockade (to 98% in both cases). The GABA-dependent component of TBPS blockade accounts for the stimulation of [(35)S]TBPS binding to α1β2γ2 receptors seen with GABA (1 μm) application. Moreover, application of GABA at concentrations that cause significant steady-state desensitization reduced [(35)S]TBPS binding. The α1(K278M) subunit slowed desensitization kinetics and increased the rate of deactivation of GABA-evoked currents. Furthermore, there was a marked increase in the GABA EC(50) for desensitization of α1(K278M)β2γ2 receptors associated with a large increase in the GABA-dependent stimulation of [(35)S]TBPS binding. These data establish a relationship between GABA(A)R function and the three phases of [(35)S]TBPS binding seen in the absence and the presence of GABA.
authors.affiliation: The Institute of Academic Anaesthesia, Division of Neuroscience, University of Dundee, Dundee DD1 9SY, UK.
authors.forename: Nidaa A
authors.initials: NA
authors.lastname: Othman
authors.forename: Michael
authors.initials: M
authors.lastname: Gallacher
authors.forename: Tarek Z
authors.initials: TZ
authors.lastname: Deeb
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Baptista-Hon
authors.forename: David C
authors.initials: DC
authors.lastname: Perry
authors.forename: Tim G
authors.initials: TG
authors.lastname: Hales
mesh_terms: D001640:Bicuculline / Q000494:pharmacology; D001665:Binding Sites; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002460:Cell Line; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology*; D005998:Glycine / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects*; D009154:Mutation; D018408:Patch-Clamp Techniques / Q000379:methods; D010852:Picrotoxin / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000378:metabolism*; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D001640:Bicuculline; D019086:Bridged Bicyclo Compounds, Heterocyclic; D058787:GABA-A Receptor Antagonists; D005998:Glycine; D010852:Picrotoxin; D011963:Receptors, GABA-A; D044406:Receptors, Serotonin, 5-HT3; D005680:gamma-Aminobutyric Acid; C037476:tert-butylbicyclophosphorothionate
references.citation: J Pharmacol Exp Ther. 2005 Jul;314(1):320-8
references.pmid: 15814570
references.citation: Prog Neurobiol. 2003 Sep;71(1):67-80
references.pmid: 14611869
references.citation: Environ Health Perspect. 1985 Sep;61:123-32
references.pmid: 2415350
references.citation: J Gen Physiol. 2007 Feb;129(2):145-59
references.pmid: 17227918
references.citation: J Neurosci. 1995 Oct;15(10):6957-62
references.pmid: 7472452
references.citation: J Neurosci. 2009 Mar 11;29(10):3083-92
references.pmid: 19279245
references.citation: Br J Pharmacol. 1995 Jul;115(6):953-60
references.pmid: 7582526
references.citation: J Membr Biol. 2001 Jun 1;181(3):171-83
references.pmid: 11420604
references.citation: J Biol Chem. 2006 Dec 15;281(50):38871-8
references.pmid: 17050528
references.citation: Nature. 2011 Jun 2;474(7349):54-60
references.pmid: 21572436
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1241-8
references.pmid: 11158624
references.citation: Br J Pharmacol. 1995 Jun;115(3):539-45
references.pmid: 7582470
references.citation: Exp Neurol. 2003 Nov;184 Suppl 1:S58-67
references.pmid: 14597328
references.citation: J Biol Chem. 2006 Jun 23;281(25):17034-17043
references.pmid: 16627470
references.citation: Mol Pharmacol. 2007 Feb;71(2):539-48
references.pmid: 17090706
references.citation: J Biol Chem. 2002 Mar 15;277(11):9112-7
references.pmid: 11744711
references.citation: J Physiol. 2006 Dec 1;577(Pt 2):569-77
references.pmid: 16990398
references.citation: J Physiol. 1994 Aug 15;479 ( Pt 1):65-75
references.pmid: 7527461
references.citation: J Physiol. 2002 Oct 1;544(Pt 1):3-18
references.pmid: 12356876
references.citation: Neurochem Int. 2009 Nov;55(6):389-96
references.pmid: 19397945
references.citation: Neurochem Int. 2007 Jan;50(1):61-8
references.pmid: 16959376
references.citation: Biochem Soc Trans. 2004 Jun;32(Pt3):529-34
references.pmid: 15157178
references.citation: Nature. 2003 Jan 16;421(6920):272-5
references.pmid: 12529644
references.citation: Br J Pharmacol. 2000 Jan;129(2):402-8
references.pmid: 10694249
references.citation: J Neurosci. 1990 Feb;10(2):603-12
references.pmid: 2303862
references.citation: Br J Pharmacol. 1997 Mar;120(5):899-909
references.pmid: 9138697
references.citation: J Physiol. 2010 Feb 15;588(Pt 4):565-72
references.pmid: 19995852
references.citation: J Physiol. 2007 Nov 1;584(Pt 3):769-87
references.pmid: 17884921
references.citation: Biophys J. 1999 Nov;77(5):2542-51
references.pmid: 10545355
references.citation: Neuron. 1989 Mar;2(3):1195-205
references.pmid: 2483110
references.citation: J Mol Biol. 2005 Mar 4;346(4):967-89
references.pmid: 15701510
references.citation: Mol Cell Biol. 1987 Aug;7(8):2745-52
references.pmid: 3670292
references.citation: Neuron. 1995 Jul;15(1):181-91
references.pmid: 7542462
references.citation: J Physiol. 1992 Feb;447:191-213
references.pmid: 1317428
references.citation: Mol Pharmacol. 1986 Oct;30(4):321-8
references.pmid: 3762521
references.citation: J Biol Chem. 2001 Mar 16;276(11):7775-81
references.pmid: 11114302
references.citation: Ann N Y Acad Sci. 1999 Apr 30;868:645-53
references.pmid: 10414349
references.citation: Br J Pharmacol. 1994 Aug;112(4):1025-30
references.pmid: 7952860
references.citation: Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):179-83
references.pmid: 11165384
references.citation: Br J Pharmacol. 2007 Apr;150(8):1066-74
references.pmid: 17339834
references.citation: Nature. 2009 Jan 1;457(7225):111-4
references.pmid: 18987633
references.citation: Neuropharmacology. 2003 Jun;44(8):994-1002
references.pmid: 12763092
references.citation: Biophys J. 2008 Jun;94(11):4299-306
references.pmid: 18310243
references.citation: Pharmacol Ther. 2006 Jan;109(1-2):12-32
references.pmid: 15996746
references.citation: J Neurosci. 2011 Feb 2;31(5):1752-61
references.pmid: 21289185
references.citation: Mol Pharmacol. 1983 Mar;23(2):326-36
references.pmid: 6300642
references.citation: Biotechniques. 2003 Sep;35(3):472-4, 476
references.pmid: 14513550
references.citation: Neuroscience. 2000;101(4):815-50
references.pmid: 11113332